Alemtuzumab



Indications and Reactions:

Role Indications Reactions
Primary
Multiple Sclerosis 31.6%
Product Used For Unknown Indication 13.6%
Prophylaxis 9.7%
T-cell Lymphoma 7.6%
Chronic Lymphocytic Leukaemia 5.9%
Immunosuppression 3.4%
Depression 3.3%
Antifungal Prophylaxis 3.3%
Antiviral Prophylaxis 2.5%
Infection Prophylaxis 2.3%
Pain 2.3%
Chronic Lymphocytic Leukaemia Recurrent 1.9%
Premedication 1.9%
Prophylaxis Against Graft Versus Host Disease 1.8%
Muscle Spasms 1.7%
Renal Transplant 1.5%
T-cell Prolymphocytic Leukaemia 1.5%
Anxiety 1.5%
Bone Marrow Conditioning Regimen 1.4%
Hypertension 1.4%
Suicidal Ideation 9.5%
Hyperthyroidism 8.2%
Thrombocytopenia 7.3%
Pyrexia 6.9%
Breast Cancer 6.5%
Pulmonary Tuberculosis 6.0%
Pleurisy 5.6%
Renal Failure Acute 5.6%
Basedow's Disease 4.7%
Multiple Sclerosis Relapse 4.7%
Cervical Dysplasia 4.3%
Rash 4.3%
Abortion Spontaneous 3.9%
Breast Mass 3.9%
Syncope 3.4%
Transplant Rejection 3.4%
Vomiting 3.4%
Gastroenteritis 3.0%
Gene Mutation 2.6%
Glomerulonephritis Membranous 2.6%
Secondary
Prophylaxis 13.4%
Multiple Sclerosis 12.7%
Chronic Lymphocytic Leukaemia 11.9%
T-cell Lymphoma 9.3%
Product Used For Unknown Indication 8.4%
Premedication 7.7%
Peripheral T-cell Lymphoma Unspecified 5.4%
Antifungal Prophylaxis 4.6%
Prophylaxis Against Graft Versus Host Disease 3.5%
Stem Cell Transplant 3.4%
Antiviral Prophylaxis 3.2%
Bone Marrow Conditioning Regimen 2.7%
Infection Prophylaxis 2.5%
Depression 2.2%
Acute Myeloid Leukaemia 1.7%
Prophylaxis Against Transplant Rejection 1.6%
Immunosuppression 1.6%
T-cell Prolymphocytic Leukaemia 1.5%
Chronic Lymphocytic Leukaemia Recurrent 1.4%
Muscle Spasms 1.1%
Thrombocytopenia 10.1%
Cytomegalovirus Infection 9.8%
Suicidal Ideation 8.8%
Sepsis 7.0%
Vomiting 6.8%
Pyrexia 6.0%
Graft Versus Host Disease 5.5%
Neutropenia 4.5%
Progressive Multifocal Leukoencephalopathy 4.5%
Pancytopenia 4.3%
Hyperthyroidism 4.0%
Transplant Rejection 4.0%
Breast Cancer 3.8%
Basedow's Disease 3.3%
Multiple Sclerosis Relapse 3.0%
Pleurisy 3.0%
Pneumonia 3.0%
Transaminases Increased 3.0%
Febrile Neutropenia 2.8%
Pneumocystis Jiroveci Pneumonia 2.8%
Concomitant
Acute Lymphocytic Leukaemia 13.4%
Large Granular Lymphocytosis 12.4%
Stem Cell Transplant 12.4%
Prophylaxis Against Graft Versus Host Disease 10.0%
Product Used For Unknown Indication 7.2%
Antifungal Prophylaxis 6.8%
Prophylaxis 5.4%
Chromosome Analysis Abnormal 4.7%
Chronic Lymphocytic Leukaemia 4.7%
Bone Marrow Conditioning Regimen 3.4%
Graft Versus Host Disease 3.2%
Renal Transplant 2.9%
Immunosuppression 2.8%
Drug Use For Unknown Indication 1.7%
Prophylaxis Against Transplant Rejection 1.6%
T-cell Lymphoma 1.6%
Bone Marrow Transplant 1.5%
Antiviral Prophylaxis 1.4%
Chemotherapy 1.4%
Immunosuppressant Drug Therapy 1.4%
Febrile Neutropenia 13.0%
Vomiting 9.0%
Sepsis 8.0%
Therapeutic Response Decreased 8.0%
Thrombocytopenia 6.0%
Pneumonia 5.0%
White Blood Cell Count Decreased 5.0%
Cystitis Viral 4.0%
Cytomegalovirus Infection 4.0%
Graft Versus Host Disease 4.0%
Neurotoxicity 4.0%
Off Label Use 4.0%
T-cell Lymphoma Recurrent 4.0%
Venoocclusive Disease 4.0%
Adenovirus Infection 3.0%
Convulsion 3.0%
Disease Progression 3.0%
General Physical Health Deterioration 3.0%
Graft Versus Host Disease In Intestine 3.0%
Malignant Neoplasm Progression 3.0%
Interacting
Cll 25.0%
Drug Use For Unknown Indication 25.0%
Prophylaxis 25.0%
Antifungal Prophylaxis 8.3%
Antiviral Prophylaxis 8.3%
Pneumocystis Carinii Prophylaxis 8.3%
Urinary Tract Infection 100.0%